Prognostic panel for urinary bladder cancer
The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and/or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.
1. A kit for prognostic use, comprising:
a single prognostic panel consisting essentially of: v-jun sarcoma virus 17 oncogene homolog (JUN), mitogen-activated protein kinase kinase 6 (MAP2K6), signal transducer and activator of transcription 3 (STAT3), and intercellular adhesion molecule 1 (ICAM1).
2. The kit of claim 1 , further comprising reference markers, detection and amplification reagents for detecting the presence of markers and/or instructions for using the single prognostic panel.
3. A method of determining a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery in an individual, comprising:
determining the presence or absence of a high level of expression in the individual relative to a normal baseline standard for a single prognostic panel consisting essentially of the following markers: JUN, MAP2K6, STAT3, and ICAM1; and
prognosing a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery if the individual demonstrates the presence of a high level of expression relative to a normal baseline standard of at least two of the markers.
4. The method of claim 3 , wherein the presence of four of said markers presents a greater likelihood of a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery than the presence of three or two of said markers, and the presence of three of said markers presents a greater likelihood of a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery than the presence of two of said markers but less than the presence of four of said markers, and the presence of two of said markers presents a greater likelihood of a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery than the presence of one or none of said markers but less than the presence of three or four of said markers.
5. The method of claim 3 , wherein the cancer is urothelial carcinoma.
6. The method of claim 3 , wherein the cancer is brain cancer, thyroid cancer, breast cancer, lung cancer, ovarian cancer, pituitary cancer and/or colon cancer.
7. A method of treating cancer characterized by disease recurrence despite possible future treatment with definitive surgery in an individual, comprising:
determining the presence or absence of a high level of expression in the individual relative to a normal baseline standard for a single prognostic panel consisting essentially of the following markers: JUN, MAP2K6, STAT3, and ICAM1;
prognosing a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery if the individual demonstrates the presence of a high level of expression relative to a normal baseline standard of at least two of the markers; and
treating the cancer with a non-surgical treatment if the individual has a prognosis of a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery.
8. The method of claim 7 , wherein the non-surgical treatment comprises chemotherapy.
9. A kit for prognostic use, comprising:
a single prognostic panel consisting essentially of: JUN, MAP2K6, STAT3, ICAM1, insulin-like growth factor 1 (IGF1), superoxide dismutase 1(SOD1), B-cell lymphoma 2 (BCL2), bone morphogenetic protein 6 (BMP6), mitogen-activated protein kinase 12 (MAPK12), tumor necrosis factor superfamily member 10 (TNFSF10), cyclin A2 (CCNA2), BCL2-like 1 (BCL2L1), transforming growth factor-beta-induced factor (TGIF), FOS-like antigen 1 (FOSL1) and glutathione S-transferase M3 (GSTM3).
10. A method of determining a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery in an individual, comprising:
determining the presence or absence of a high level of expression in the individual relative to a normal baseline standard for a single prognostic panel consisting essentially of the following markers: JUN, MAP2K6, STAT3, ICAM1, IGF1, SOD1, BCL2, BMP6, MAPK12, TNFSF10, CCNA2, BCL2L1, TGIF, FOSL1 and GSTM3; and
prognosing a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery if the individual demonstrates the presence of a high level of expression relative to a normal baseline standard of one or more of the markers.
11. A kit for prognostic use, comprising:
a single prognostic panel consisting essentially of: JUN, MAP2K6, STAT3, ICAM1, IGF1, SOD1, BCL2, and BMP6.
12. A method of determining a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery in an individual, comprising:
determining the presence or absence of a high level of expression in the individual relative to a normal baseline standard for a single prognostic panel consisting essentially of: JUN, MAP2K6, STAT3, ICAM1, IGF1, SOD1, BCL2, and BMP6; and
prognosing a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery if the individual demonstrates the presence of a high level of expression relative to a normal baseline standard of one or more of the markers.
13. A kit for prognostic use, comprising:
a single prognostic panel consisting essentially of: MAPK12, JUN, TNFSF10, CCNA2, TGIF, MAP2K6, BCL2L1, STAT3, ICAM1, FOSL1, and GSTM3.
14. A method of determining a prognosis of cancer characterized by disease recurrence despite possible future treatment with definitive surgery in an individual, comprising:
determining the presence or absence of a high level of expression in the individual relative to a normal baseline standard for a single prognostic panel consisting essentially of: MAPK12, JUN, TNFSF10, CCNA2, TGIF, MAP2K6, BCL2L1, STAT3, ICAM1, FOSL1, and GSTM3; and
prognosing a case of cancer characterized by disease recurrence despite possible future treatment with definitive surgery if the individual demonstrates the presence of a high level of expression relative to a normal baseline standard of one or more of the markers.